Published January 29, 2026 | Version v.1

Innate lymphoid cells: Dual roles and therapeutic opportunities in breast cancer

  • 1. Department of Immunology, Institute for Biological Research "Siniša Stanković" - National Institute of the Republic of Serbia
  • 2. Department of Immunology, Institute for Biological Research "Siniša Stanković" - National Institute of the Republic of Serbia, University of Belgrade
  • 3. Department for Medical Oncology, Institute for Oncology and Radiology, Belgrade, Serbia
  • 4. Department of Radiation Oncology, Institute for Oncology and RadiologyThe institution will open in a new tab, Belgrade, Serbia
  • 5. Department of Immunology, Ophthalmology, and ENT, Universidad Complutense de Madrid
  • 6. Instituto de Investigación Sanitaria Hospital 12 de Octubre (Imas12), Madrid, Spain

Description

Abstract

Innate lymphoid cells (ILC) play a crucial role in shaping immune responses and maintaining tissue homeostasis. Recent research has identified their involvement in breast cancer pathogenesis, mainly through shaping the tumor microenvironment, where they can exert dual roles, either promoting tumor eradication by enhancing anti-tumor immunity, or facilitating tumor progression through mechanisms of immune evasion. This functional plasticity makes ILC attractive targets for immunotherapy. Furthermore, their slow proliferation enables them to survive anti-proliferative radiation therapy and chemotherapy, which may support continuous immune surveillance of breast cancer tissue. However, this same resilience poses a significant challenge, as surviving ILC could contribute to tumor persistence or recurrence. Additionally, anti-estrogen therapy, chemotherapy and immune checkpoint inhibitors, commonly used in breast cancer treatment, may interfere with ILC function, either dampening their anti-tumor potential or enhancing their pro-tumor activities. Understanding the complex interactions between ILC and conventional therapies is critical for designing effective immunotherapeutic approaches that include ILC targeting, potentially overcoming resistance and improving patient outcomes in breast cancer therapy.

Notes (English)

The authors acknowledge financial support by the Ministry of Science, Innovation and Technological Development of the Republic of Serbia (contract No 451–03–136/2025–03/ 200007)

The authors acknowledge financial support by the Ministry of Science, Innovation and Technological Development of the Republic of Serbia (contract No 451\u201303\u2013136/2025\u201303/ 200007 ).

See opportunities by MESTSee opportunities (opens in new window) 451–03–136/2025–03/ 200007

Files

1-s2.0-S0165247825000847-main.pdf

Files (1.3 MB)

Name Size
md5:cd56bd3aad187feb7e852615ed25f639
1.3 MB Preview Download

Additional details

Identifiers

ISSN
0165-2478
PMID
40490082

Dates

Accepted
2026-01-27
Available
2026-01-29

Software

Repository URL
https://zenodo.org/uploads/18632060
Development Status
Active